Trials / Completed
CompletedNCT00536692
Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- CoMentis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mecamylamine | topical ocular drops |
Timeline
- Start date
- 2007-09-01
- Completion
- 2008-04-01
- First posted
- 2007-09-28
- Last updated
- 2008-04-08
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00536692. Inclusion in this directory is not an endorsement.